Actively Recruiting

Phase Not Applicable
Age: 2Years +
All Genders
NCT07445438

Feasibility of a Multi-omics Platform for Hematological Malignancies

Led by Azienda Ospedaliero-Universitaria di Parma · Updated on 2026-03-03

1040

Participants Needed

1

Research Sites

256 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This is a biological study based on a collaborative effort involving several Italian haematology centres (including the coordinating centre). The study will be conducted retrospectively and prospectively using bone marrow (BM) or peripheral blood (PB) samples, lymph node or tissue biopsies with metastatic involvement, and other biological fluids, such as cerebrospinal fluid and pathological pleural effusion.

CONDITIONS

Official Title

Feasibility of a Multi-omics Platform for Hematological Malignancies

Who Can Participate

Age: 2Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patient aged > 2 years old
  • For retrospective study: Patients previously diagnosed with hematological malignancies
  • For prospective study: Patients with clinical suspicion of hematological malignancies requiring diagnostic assessment using bone marrow or peripheral blood samples, lymph node or tissue biopsies with metastatic involvement, or other biological fluids such as cerebrospinal fluid or pathological pleural effusion
  • Patients suspected of relapse/refractory onco-hematological disorder requiring diagnostic assessment using bone marrow aspirate/biopsy, tissue biopsies including lymph nodes, cerebrospinal fluid from lumbar puncture, or tissue aspirate
  • Patients with blastic transformation from a chronic condition or suspected relapse/refractory hematological disease requiring diagnostic assessment using peripheral blood, bone marrow aspirate/biopsy, lymph node biopsies, or biopsies of tissues with metastatic involvement including cerebrospinal fluid from lumbar puncture or tissue aspirate
Not Eligible

You will not qualify if you...

  • Age less than 2 years old
  • Patients without a diagnosis of hematological malignancy

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

University of Parma

Parma, PR, Italy, 43126

Actively Recruiting

Loading map...

Research Team

G

Giovanni Roti, Associate Professor

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

BASIC_SCIENCE

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Feasibility of a Multi-omics Platform for Hematological Malignancies | DecenTrialz